Ind-Swift Laboratories Limited (INDSWFTLAB.BO)
INR 88.74
(-1.81%)
INR 88.74
(-1.81%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 4.42 Billion INR | 15.77% |
| 2022 | 1.73 Billion INR | 121.04% |
| 2021 | 785.09 Million INR | -19.19% |
| 2020 | 971.51 Million INR | 77.27% |
| 2019 | 548.04 Million INR | 147.85% |
| 2018 | 221.11 Million INR | -53.75% |
| 2017 | 478.09 Million INR | 181.92% |
| 2016 | -583.58 Million INR | 31.66% |
| 2015 | -853.91 Million INR | 40.97% |
| 2014 | -1.44 Billion INR | -0.44% |
| 2013 | -1.44 Billion INR | -11.05% |
| 2012 | -1.29 Billion INR | -253.78% |
| 2011 | 843.46 Million INR | -41.78% |
| 2010 | 1.44 Billion INR | 36.04% |
| 2009 | 1.06 Billion INR | 7.1% |
| 2008 | 994.41 Million INR | 35.7% |
| 2007 | 732.83 Million INR | 45.34% |
| 2006 | 504.2 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -99.9 Million INR | 100.0% |
| 2023 Q1 | 464.14 Million INR | -16.26% |
| 2023 FY | 2 Billion INR | 15.77% |
| 2023 Q4 | -499.74 Million INR | -210.45% |
| 2023 Q3 | 452.48 Million INR | -13.82% |
| 2023 Q2 | 525.07 Million INR | 13.13% |
| 2022 Q1 | 367.27 Million INR | 181.4% |
| 2022 FY | 1.73 Billion INR | 121.04% |
| 2022 Q4 | 554.27 Million INR | 44.44% |
| 2022 Q3 | 383.73 Million INR | -9.38% |
| 2022 Q2 | 423.45 Million INR | 15.3% |
| 2021 Q1 | 371.88 Million INR | 171.14% |
| 2021 Q4 | -451.18 Million INR | -244.92% |
| 2021 Q3 | 311.33 Million INR | -26.13% |
| 2021 Q2 | 421.47 Million INR | 13.34% |
| 2021 FY | 785.09 Million INR | -19.19% |
| 2020 FY | 971.51 Million INR | 77.27% |
| 2020 Q2 | 348.77 Million INR | 17.77% |
| 2020 Q3 | 374.53 Million INR | 7.38% |
| 2020 Q4 | 137.15 Million INR | -63.38% |
| 2020 Q1 | 296.14 Million INR | -25.33% |
| 2019 Q4 | 396.59 Million INR | 63.26% |
| 2019 FY | 548.04 Million INR | 147.85% |
| 2019 Q3 | 242.91 Million INR | 41.69% |
| 2019 Q2 | 171.44 Million INR | -25.08% |
| 2019 Q1 | 228.83 Million INR | 91.85% |
| 2018 Q2 | 190.64 Million INR | 110.49% |
| 2018 FY | 221.11 Million INR | -53.75% |
| 2018 Q4 | 119.28 Million INR | -31.89% |
| 2018 Q1 | 90.56 Million INR | 0.0% |
| 2018 Q3 | 175.12 Million INR | -8.14% |
| 2017 FY | 478.09 Million INR | 181.92% |
| 2016 FY | -583.58 Million INR | 31.66% |
| 2015 FY | -853.91 Million INR | 40.97% |
| 2014 FY | -1.44 Billion INR | -0.44% |
| 2013 FY | -1.44 Billion INR | -11.05% |
| 2012 Q2 | 178.07 Million INR | 182.81% |
| 2012 FY | -1.29 Billion INR | -253.78% |
| 2012 Q3 | 172.02 Million INR | -3.4% |
| 2012 Q1 | -215.03 Million INR | 0.0% |
| 2012 Q4 | -453.8 Million INR | -363.8% |
| 2011 FY | 843.46 Million INR | -41.78% |
| 2010 FY | 1.44 Billion INR | 36.04% |
| 2009 FY | 1.06 Billion INR | 7.1% |
| 2008 FY | 994.41 Million INR | 35.7% |
| 2007 FY | 732.83 Million INR | 45.34% |
| 2006 FY | 504.2 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Bal Pharma Limited | 233.9 Million INR | -1789.859% |
| Achyut Healthcare Limited | 4.43 Million INR | -99506.805% |
| Alkem Laboratories Limited | 19.46 Billion INR | 77.286% |
| Divi's Laboratories Limited | 33.08 Billion INR | 86.637% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 32.016% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 50.769% |
| Krebs Biochemicals & Industries Limited | -151.95 Million INR | 3009.08% |
| Mankind Pharma Limited | 21.51 Billion INR | 79.457% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Medico Remedies Limited | 100.3 Million INR | -4307.328% |
| Megasoft Limited | -121.1 Million INR | 3750.21% |
| Procter & Gamble Health Limited | 2.78 Billion INR | -58.67% |
| Piramal Pharma Limited | 4.55 Billion INR | 2.992% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Sigachi Industries Limited | 1.47 Billion INR | -199.923% |
| Ajanta Pharma Limited | 19.67 Billion INR | 77.535% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 95.762% |
| Brooks Laboratories Limited | 14.44 Million INR | -30513.227% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | -41.317% |
| Themis Medicare Limited | 392.58 Million INR | -1025.999% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Hester Biosciences Limited | 364.81 Million INR | -1111.74% |
| Venus Remedies Limited | 534.65 Million INR | -726.81% |
| Indoco Remedies Limited | 1.29 Billion INR | -242.003% |
| Ind-Swift Limited | 1.22 Billion INR | -260.577% |
| Aarti Drugs Limited | 7.14 Billion INR | 38.163% |
| Alpa Laboratories Limited | 184.49 Million INR | -2296.001% |
| AstraZeneca Pharma India Limited | 1.71 Billion INR | -157.383% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 93.473% |
| Granules India Limited | 6.81 Billion INR | 35.151% |
| Gufic Biosciences Limited | 1.32 Billion INR | -232.395% |
| Hikal Limited | 32.11 Million INR | -13666.895% |
| RPG Life Sciences Limited | 2.29 Billion INR | -92.843% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 4.06% |
| Windlas Biotech Limited | 1.29 Billion INR | -240.333% |
| ZIM Laboratories Limited | 253.82 Million INR | -1641.546% |
| IOL Chemicals and Pharmaceuticals Limited | 1.59 Billion INR | -176.838% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 14.809% |
| Aurobindo Pharma Limited | 42.2 Billion INR | 89.526% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Biofil Chemicals and Pharmaceuticals Limited | 9.06 Million INR | -48645.134% |
| Ipca Laboratories Limited | 7.98 Billion INR | 44.609% |
| Lasa Supergenerics Limited | -458 Million INR | 1065.175% |
| Laurus Labs Limited | 3.94 Billion INR | -11.952% |
| NATCO Pharma Limited | 25.96 Billion INR | 82.973% |
| Nectar Lifesciences Limited | 923.8 Million INR | -378.515% |
| Shilpa Medicare Limited | 1.36 Billion INR | -223.548% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 214.733% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 82.552% |
| Wanbury Limited | 569.71 Million INR | -675.922% |
| Wockhardt Limited | -670 Million INR | 759.784% |
| Strides Pharma Science Limited | 5.22 Billion INR | 15.409% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | -259.102% |
| Suven Life Sciences Limited | -1.22 Billion INR | 460.619% |
| Amrutanjan Health Care Limited | 457.54 Million INR | -866.148% |
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 23.229% |
| Eris Lifesciences Limited | 5.18 Billion INR | 14.69% |
| Lupin Limited | 28.04 Billion INR | 84.237% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 207.424% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -1673.534% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| Zydus Lifesciences Limited | 43.1 Billion INR | 89.745% |
| FDC Limited | 2.98 Billion INR | -48.032% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.28 Billion INR | 69.05% |
| Novartis India Limited | 626.5 Million INR | -605.595% |
| Jagsonpal Pharmaceuticals Limited | 508.13 Million INR | -769.964% |
| Neuland Laboratories Limited | 5.31 Billion INR | 16.877% |
| Morepen Laboratories Limited | 4.17 Billion INR | -5.911% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -2024.754% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -15999.315% |